* Alnylam presents updated results from phase 1/2 study of
aln-cc5 in patients with paroxysmal nocturnal hemoglobinuria
(pnh)
The post BRIEF-Alnylam presents updated results from phase 1/2 study of ALN-CC5 in patients with paroxysmal nocturnal hemoglobinuria appeared first on NASDAQ.